465 Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@PID LUNG 024 study

• Francois Ghiringhelli,
• Sandrine Hiret,
• Christian Rolfo,
• Christoph Helwig,
• Nicolas Isambert,
• Yulia Vugmeyster,
• Rémi Veillon,
• Laurent Greillier,
• Firas Badin,
• Astrid Paulus,
• Marc Lambrechts,
• Surendra Chaudhary,
• Xiaoli You

Affiliations

Francois Ghiringhelli

Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France

Sandrine Hiret

11Institut de Cancérologie de l’Ouest, Saint-Herblain, France, Saint Herblain, France

Christian Rolfo

Center for Thoracic Oncology at Tisch Cancer Institute, Mount Sinai Health System & Icahn School of Medicine at Mount Sinai, New York, New York, USA

Christoph Helwig

Merck KGaA, Darmstadt, Germany

Nicolas Isambert

2Medical Oncology, Sevilla, Spain

Yulia Vugmeyster

7EMD Serono Research and Development Institute, Inc., Billerica, Massachusetts, USA; a business of Merck KGaA, Darmstadt, Germany, Billerica, MA, USA

Rémi Veillon

2 Pulmonology Department, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France

Laurent Greillier

15APHM, Aix Marseille Université, Marseille, France

Firas Badin

4Baptist Health Lexington, Lexington, KY, USA, Lexington, KY, USA

Astrid Paulus

7CHU Sart Tilman, Liege, Belgium, Liege, Belgium

Marc Lambrechts

8Algemeen Ziekenhuis Sint-Maarten, Mechelen, Belgium, Mechelen, Belgium

Surendra Chaudhary

9EMD Serono, Billerica, MA USA, Billerica, MA, USA

Xiaoli You

9EMD Serono, Billerica, MA USA, Billerica, MA, USA